Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 10/20 | 0.48 |
| ▸ | MAOA | P21397 | 9/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253035 | 0.81 | SLC6A4 (0.44) | ARALDH1A1SLC6A4KDM4EHSD17B10 | |
| SCHEMBL516309 | 0.77 | ALDH1A1 (0.52) | MAOBMAOAKIF11CYP2A6ALDH1A1 | |
| SCHEMBL4888690 | 0.77 | SLC22A12 (0.57) | MAOBMAOA | |
| SCHEMBL28169917 | 0.76 | MAOB (0.50) | ARMAOBMAOAKIF11CYP2A6 | |
| SCHEMBL5313238 | 0.75 | AR (0.47) | ARMAOBMAOAKIF11TSHR | |
| SCHEMBL7379684 | 0.74 | AR (0.42) | ARKIF11SLC6A4KDM4EHSD17B10 | |
| SCHEMBL18245275 | 0.74 | SLC6A4 (0.39) | ARSLC6A4KDM4EHSD17B10 | |
| SCHEMBL1145161 | 0.73 | MAOB (0.54) | MAOBMAOAKIF11CYP2A6ALDH1A1 | |
| SCHEMBL13319330 | 0.72 | MAOB (0.53) | MAOBMAOAKIF11CYP2A6ALDH1A1 | |
| SCHEMBL28489628 | 0.72 | AR (0.67) | ARMAOBMAOAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108003113-A | A kind of synthetic method for treating diabetes medicament | 上海工程技术大学 | 2018-05-08 | — | — | CN | claimed |
| CN-108003113-A | A kind of synthetic method for treating diabetes medicament | 上海工程技术大学 | 2018-05-08 | — | — | CN | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1423381-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1423381-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7138396-B2 | 17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060069103-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-20060014755-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | MERCK SHARP & DOHME CORP. | 2006-01-19 | — | — | US | disclosed |
| US-6903102-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040132736-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION | 2004-07-08 | — | — | US | disclosed |
| EP-1423381-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | Schering Corporation (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003022835-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069103-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | HSD17B3, HSD17B1, HSD17B11 | AR 40/4885MAOB 304/4885MAOA 372/4885 |
| US-20040132736-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | HSD17B3, HSD17B1, HSD17B11 | AR 45/4885MAOB 307/4885MAOA 366/4885 |
| US-20060014755-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | HSD17B3, HSD17B1, HSD17B11 | AR 39/4885MAOB 295/4885MAOA 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.